$2.87
11.24% today
Nasdaq, Nov 17, 10:13 pm CET
ISIN
US29479A1088
Symbol
ERAS

Erasca Inc Stock price

$2.87
+0.45 18.60% 1M
+1.64 133.33% 6M
+0.36 14.34% YTD
+0.14 5.13% 1Y
-4.72 62.19% 3Y
-14.56 83.53% 5Y
-14.56 83.53% 10Y
-14.56 83.53% 20Y
Nasdaq, Closing price Mon, Nov 17 2025
+0.29 11.24%
ISIN
US29479A1088
Symbol
ERAS
Industry

Key metrics

Basic
Market capitalization
$732.0m
Enterprise Value
$431.3m
Net debt
positive
Cash
$300.7m
Shares outstanding
283.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
84.3%
Return on Equity
-38.2%
ROCE
-33.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-135.9m | $-148.2m
EBIT
$-139.2m | $-150.5m
Net Income
$-128.3m | $-126.7m
Free Cash Flow
$-99.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.6% | 0.3%
EBIT
5.9% | 1.2%
Net Income
19.0% | 21.7%
Free Cash Flow
11.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.3
Short interest
6.5%
Employees
103
Rev per Employee
$0.0
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Erasca Inc forecast:

13x Buy
81%
2x Hold
13%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Erasca Inc forecast:

Buy
81%
Hold
13%
Sell
6%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 38 38
3% 3%
-
- Research and Development Expense 101 101
7% 7%
-
-136 -136
6% 6%
-
- Depreciation and Amortization 3.28 3.28
18% 18%
-
EBIT (Operating Income) EBIT -139 -139
6% 6%
-
Net Profit -128 -128
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
5 days ago
U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities...
Neutral
GlobeNewsWire
11 days ago
The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043  Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerciali...
Neutral
GlobeNewsWire
13 days ago
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investo...
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 103
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today